http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2748434-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d6f7da1e425c8a3ef1da21e08f4c196 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06139 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06191 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0806 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0606 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06069 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06086 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06104 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-062 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-083 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-097 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2015-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e18e81406bda95038eab8e6b69f5b7e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ae4f7dd168a37dbe1569615980f7e33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d894082be33bff7c308adc0e215932ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c8b7327b6bc992988d2bfc2ab1831b3 |
| publicationDate | 2020-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2748434-T3 |
| titleOfInvention | Dipeptides as inhibitors of human immunoproteasomes |
| abstract | A compound of Formula (Ia): ** Formula ** wherein R1a is selected from the group consisting of bicyclic aryl, monocyclic and bicyclic heteroaryl, and monocyclic and bicyclic non-aromatic heterocycle, wherein bicyclic aryl, monocyclic and bicyclic heteroaryl, and Monocyclic and bicyclic non-aromatic heterocycle may optionally be substituted 1 to 3 times with a substituent independently selected at each occurrence thereof from the group consisting of halogen, cyano, C1-6 alkyl and C1-6 alkoxy; R2a is selected from the group consisting of C1-6 alkyl, -CH2OC1-6alkyl, -CH2Ar, and heteroaryl, wherein the aryl (Ar) may be optionally substituted 1 to 3 times with an independently selected substituent at each occurrence of the group that consists of halogen, cyano, C1-6 alkyl and C1-6 alkoxy; R3a is selected from the group consisting of N-CH2OC1-6 alkyl, -CH2C (O) NHR5a and -CH2C (O) R5a; R4a is selected from the group consisting of eN-C (O) (CH2) nPh, - C (O) CH2NR6aR7a, - SO2Ar, - SO2C1-6alkyl, - C (O) (CH2) nHet, - C (O) C1 - 6 alkyl, -C (O) CF3, heteroaryl, and - (CH2) nNR6aR7a, where aryl (Ar) and heteroaryl (Het) may be optionally substituted 1 to 3 times with an independently selected substituent at each occurrence of the group consisting in halogen, cyano, C1-6 alkyl and C1-6 alkoxy; R5a is selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, non-aromatic heterocycle, and -CR8aR9a; R6a, R7a, R8a, and R9a are each independently selected from the group consisting of H, C1-6 alkyl, and - (CH2) kOH; or R6a and R7a are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, azepane, azetidine or morpholine ring; or R8a and R9a are taken together with the carbon to which they are attached to form an oxetane ring; n is 0, 1, 2 or 3; and k is 1, 2 or 3, a pharmaceutically acceptable salt thereof or a solvate thereof. |
| priorityDate | 2014-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 606.